JAKARTA, Indonesia, June 20, 2025 /PRNewswire/ -- Taman Safari Indonesia (TSI) continues to hold the 34th edition of International Animal Photo & Video Competition (IAPVC) under the theme "The Picture of Nature's Secret", reinforcing its commitment to conservation through visual storytelling.
Hans Manansang, Director of Commercial & Business Taman Safari Indonesia highlighted the power of digital media in raising awareness. "With over 4.9 billion social media users worldwide, visual content is 40% more effective in conveying messages. IAPVC has the potential to bridge creative expression with environmental consciousness in a relevant and impactful way."
To embrace current trends, IAPVC 2025 introduces a video category, encouraging broader creative participation. TSI will also hold an IAPVC Roadshow across its three major parks: Taman Safari Solo, Taman Safari Bogor, and Taman Safari Prigen.
Rizki Handayani, Deputy of Industry and Investment at the Ministry of Tourism, emphasized that conservation cannot be accomplished in isolation. Competitions like IAPVC serve as important platforms to foster public participation through cross-sector creative approaches. The Ministry of Tourism also expressed appreciation for TSI's consistent efforts in organizing IAPVC as a valuable contribution to Indonesia's creative economy.
"This competition proves that visual works are not only artistically valuable but also carry significant economic potential and social impact."
Since its inception in 1991, IAPVC has grown into a global competition. In 2024, the competition welcomed more than 8,000 participants and received over 23,000 entries.
Running from June 12 to August 30, 2025, the competition is inviting professional photographers, photography enthusiasts, creative communities, and social media content creators. The 34th IAPVC will also feature a jury panel composed of professional photographers and journalists.
The launch of IAPVC 2025 concluded with a spectacular performance of the LILA Show, an iconic presentation at Enchanting Valley that embodies the spirit of conservation advocacy. For more information please visit https://iapvc.tamansafari.com/
Through initiatives such as IAPVC, Taman Safari Indonesia continues to affirm its global leadership in conservation, uniting creativity and advocacy to protect endangered wildlife. With four international certifications and over 20 national awards, Taman Safari remains a proud symbol of Indonesia's commitment to conservation and education. For further information about Taman Safari Indonesia please visit https://tamansafari.com/. Let every creation be a voice for the Earth, its wildlife, and our shared future.
Contact Person:
Finky Santika NH
Head of Media and Digital Taman Safari Indonesia Group
head.media@tamansafari.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
34 Years of Advocating Conservation Through Visual Storytelling, Taman Safari Continues to Hold the International Animal Photo & Video Competition
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
